Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of bevacizumab and irinotecan in recurrent primary malignant brain tumors
2006-006011-74Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Dec 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and irinotecan in primary brain cancer, sponsored by Rigshospitalet. Primary endpoints: Disease control rate, Progression-free survival and 2 more. Started Dec 2006; status: completed.
02
Drugs
bevacizumabirinotecan
03
Conditions
primary brain cancer
Beyond the preview
Go deeper on 2006-006011-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006011-74.